Iradimed Corporation (NASDAQ:IRMD - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $58.00 and last traded at $57.11, with a volume of 30305 shares changing hands. The stock had previously closed at $56.71.
Iradimed Stock Performance
The stock has a market cap of $737.70 million, a P/E ratio of 39.87 and a beta of 0.81. The stock has a 50-day moving average price of $53.91 and a 200-day moving average price of $49.40.
Iradimed Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.03%. Iradimed's payout ratio is presently 41.10%.
Insider Transactions at Iradimed
In other news, CFO John Glenn sold 2,500 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 37.10% of the company's stock.
Institutional Trading of Iradimed
Hedge funds and other institutional investors have recently bought and sold shares of the company. Huntington National Bank lifted its holdings in shares of Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock worth $75,000 after acquiring an additional 504 shares during the last quarter. Gladius Capital Management LP lifted its stake in Iradimed by 126.6% in the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider's stock worth $87,000 after purchasing an additional 965 shares during the last quarter. Quantbot Technologies LP boosted its position in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock valued at $117,000 after buying an additional 1,052 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Iradimed during the third quarter valued at about $126,000. Finally, SG Americas Securities LLC purchased a new position in shares of Iradimed in the third quarter worth about $147,000. Hedge funds and other institutional investors own 92.34% of the company's stock.
About Iradimed
(
Get Free Report)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
See Also
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
